RS62634B1 - Čvrsti kristalni oblici 6-karboksi-2-(3,5-dihlorofenil)-benzoksazola - Google Patents

Čvrsti kristalni oblici 6-karboksi-2-(3,5-dihlorofenil)-benzoksazola

Info

Publication number
RS62634B1
RS62634B1 RS20211481A RSP20211481A RS62634B1 RS 62634 B1 RS62634 B1 RS 62634B1 RS 20211481 A RS20211481 A RS 20211481A RS P20211481 A RSP20211481 A RS P20211481A RS 62634 B1 RS62634 B1 RS 62634B1
Authority
RS
Serbia
Prior art keywords
solid
crystalline form
peaks
less
dichlorophenyl
Prior art date
Application number
RS20211481A
Other languages
English (en)
Serbian (sr)
Inventor
Kevin Paul Girard
Andrew J Jensen
Kris Nicole Jones
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54199901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62634(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of RS62634B1 publication Critical patent/RS62634B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
RS20211481A 2014-09-08 2015-08-31 Čvrsti kristalni oblici 6-karboksi-2-(3,5-dihlorofenil)-benzoksazola RS62634B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462047614P 2014-09-08 2014-09-08
US201562203953P 2015-08-12 2015-08-12
EP15771276.1A EP3191461B1 (en) 2014-09-08 2015-08-31 Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
PCT/IB2015/056597 WO2016038500A1 (en) 2014-09-08 2015-08-31 Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole

Publications (1)

Publication Number Publication Date
RS62634B1 true RS62634B1 (sr) 2021-12-31

Family

ID=54199901

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211481A RS62634B1 (sr) 2014-09-08 2015-08-31 Čvrsti kristalni oblici 6-karboksi-2-(3,5-dihlorofenil)-benzoksazola

Country Status (24)

Country Link
US (1) US9770441B1 (enExample)
EP (3) EP3191461B1 (enExample)
JP (5) JP2016065042A (enExample)
KR (1) KR102004059B1 (enExample)
CN (2) CN115368313A (enExample)
AU (1) AU2015313875B2 (enExample)
BR (1) BR112017003421B1 (enExample)
CA (1) CA2903194A1 (enExample)
CY (1) CY1124843T1 (enExample)
DK (1) DK3977993T3 (enExample)
ES (2) ES2975633T3 (enExample)
FI (1) FI3977993T3 (enExample)
HR (1) HRP20211834T1 (enExample)
HU (2) HUE065233T2 (enExample)
IL (1) IL251037B1 (enExample)
LT (1) LT3191461T (enExample)
MX (1) MX374012B (enExample)
PL (2) PL3977993T3 (enExample)
PT (2) PT3191461T (enExample)
RS (1) RS62634B1 (enExample)
SG (1) SG11201700958YA (enExample)
SI (2) SI3977993T1 (enExample)
TW (1) TWI644902B (enExample)
WO (1) WO2016038500A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
PL3953339T3 (pl) * 2019-04-11 2025-05-05 Inke, S.A. Proces otrzymania 1-deoksy-1-metyloamino-d-glucitolu 2-(3,5-dichlorofenylo)-6-benzoksazolokarboksylanu
US12391656B2 (en) 2019-05-16 2025-08-19 Assia Chemical Industries Ltd. Solid state forms of Tafamidis and salts thereof
WO2021001858A1 (en) * 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
EP4059926A4 (en) 2019-11-15 2022-12-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF TAFAMIDIS AND PROCESS FOR PRODUCTION AND USE THEREOF
EP4077287B1 (en) * 2019-12-20 2025-11-19 Pfizer Ireland Pharmaceuticals Unlimited Company Efficient process for making 6-carboxy benzoxazole derivatives
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
WO2021232619A1 (zh) * 2020-05-19 2021-11-25 苏州科睿思制药有限公司 一种他发米帝司游离酸的晶型及其制备方法和用途
US20230265059A1 (en) * 2020-07-04 2023-08-24 Nuray Chemicals Private Limited Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof
WO2022084790A1 (en) * 2020-10-19 2022-04-28 Glenmark Life Sciences Limited Process for preparation of tafamidis and salts thereof
WO2022107166A1 (en) * 2020-11-20 2022-05-27 Natco Pharma Limited Novel crystalline form of tafamidis and its process thereof
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN114907283B (zh) * 2021-02-07 2025-01-28 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
CN114989106A (zh) * 2021-02-09 2022-09-02 齐鲁制药有限公司 氯苯唑酸的新晶型及其制备方法
EP4083027A1 (en) 2021-04-26 2022-11-02 Química Sintética, S.A. A solid state form of tafamidis and a process for its preparation
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
JP2024541422A (ja) 2021-11-17 2024-11-08 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー タファミジスの固体状態の形態
KR20250036933A (ko) 2022-07-28 2025-03-14 화이자 인코포레이티드 타파미디스 약학 조성물
WO2024084362A1 (en) * 2022-10-17 2024-04-25 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of crystalline form of tafamidis
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis
US11980685B1 (en) 2022-12-23 2024-05-14 Tap Pharmaceuticals, Ag Liquid pharmaceutical formulations of tafamidis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DK1587821T6 (da) 2002-12-19 2025-05-26 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
CA2669849C (en) * 2006-12-06 2012-01-31 Pfizer Inc. Crystalline forms of (3s)-3-[n-(n'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
SG2014013270A (en) * 2011-09-16 2014-05-29 Pfizer Solid forms of a transthyretin dissociation inhibitor
US9499527B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
US12391656B2 (en) 2019-05-16 2025-08-19 Assia Chemical Industries Ltd. Solid state forms of Tafamidis and salts thereof
WO2021001858A1 (en) 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
WO2021152623A1 (en) 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt

Also Published As

Publication number Publication date
RU2017107235A (ru) 2018-10-11
KR102004059B1 (ko) 2019-07-25
TW201613880A (en) 2016-04-16
BR112017003421B1 (pt) 2023-10-10
EP3191461A1 (en) 2017-07-19
JP2023134645A (ja) 2023-09-27
RU2017107235A3 (enExample) 2018-10-11
AU2015313875B2 (en) 2018-03-15
LT3191461T (lt) 2021-12-10
IL251037A0 (en) 2017-04-30
EP4349406B1 (en) 2025-12-03
PT3191461T (pt) 2021-12-27
AU2015313875A1 (en) 2017-03-02
IL251037B1 (en) 2024-10-01
SI3977993T1 (sl) 2024-05-31
CA2903194A1 (en) 2016-03-08
NZ766084A (en) 2023-12-22
FI3977993T3 (fi) 2024-03-25
JP2022024014A (ja) 2022-02-08
MX2017002954A (es) 2017-06-15
JP2016065042A (ja) 2016-04-28
EP3191461B1 (en) 2021-11-03
DK3977993T3 (da) 2024-02-19
EP3977993B1 (en) 2024-01-31
CY1124843T1 (el) 2022-11-25
PL3977993T3 (pl) 2024-05-06
KR20170040314A (ko) 2017-04-12
PL3191461T3 (pl) 2022-02-07
BR112017003421A2 (pt) 2017-11-28
PT3977993T (pt) 2024-04-01
TWI644902B (zh) 2018-12-21
SI3191461T1 (sl) 2022-01-31
CN115368313A (zh) 2022-11-22
JP7357525B2 (ja) 2023-10-06
HRP20211834T1 (hr) 2022-03-04
US9770441B1 (en) 2017-09-26
RU2692252C2 (ru) 2019-06-24
US20170273953A1 (en) 2017-09-28
JP2025108584A (ja) 2025-07-23
WO2016038500A1 (en) 2016-03-17
ES2901785T3 (es) 2022-03-23
CN106715405A (zh) 2017-05-24
EP4349406A2 (en) 2024-04-10
ES2975633T3 (es) 2024-07-10
JP2020055832A (ja) 2020-04-09
EP3977993A1 (en) 2022-04-06
HUE065233T2 (hu) 2024-05-28
HUE056583T2 (hu) 2022-02-28
MX374012B (es) 2020-07-22
SG11201700958YA (en) 2017-03-30
EP4349406A3 (en) 2024-05-22
NZ729011A (en) 2023-10-27

Similar Documents

Publication Publication Date Title
RS62634B1 (sr) Čvrsti kristalni oblici 6-karboksi-2-(3,5-dihlorofenil)-benzoksazola
WO2013038351A1 (en) Solid forms of a transthyretin dissociation inhibitor
US20240199585A1 (en) Solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
CN117062808A (zh) Bcl的结晶固体葡甲胺盐抑制剂及其制备和使用方法
EP3453712B1 (en) Diethylamine solvate of sodium-glucose linked transporter inhibitor, and preparation method and application thereof
WO2019080865A1 (zh) 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法
CA3042738A1 (en) Novel crystalline forms of lesinurad
JP2023536911A (ja) Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤の結晶形態
HK40083489A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
NZ729011B2 (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
HK1237336A1 (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
WO2025149547A1 (en) New solid forms of n-[(1s,2e)-1-cyclopropyl-3-(methanesulfonyl)prop-2-en-1-yl]-2- (1,1-difluoroethyl)-4- phenoxypyrimidine-5-carboxamide
KR20240168375A (ko) 고순도 화합물의 제조 방법 및 정제 방법
HK40063558B (zh) 苯幷噻唑化合物的药用盐、多晶型物及其制备方法
EA043335B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
NZ621194B2 (en) Solid forms of a transthyretin dissociation inhibitor